Codexis (NASDAQ:CDXS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Earnings & Valuation
This table compares Codexis and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Codexis | $68.46 million | 23.09 | $-11,940,000.00 | ($0.21) | -116.90 |
Regeneron Pharmaceuticals | $7.86 billion | 6.74 | $2.12 billion | $21.47 | 23.04 |
Regeneron Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Codexis and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Codexis | -31.08% | -21.25% | -14.33% |
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Insider & Institutional Ownership
91.3% of Codexis shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Codexis and Regeneron Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Codexis | 0 | 0 | 5 | 0 | 3.00 |
Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Regeneron Pharmaceuticals has a consensus price target of $646.2609, suggesting a potential upside of 30.65%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Codexis.
Summary
Regeneron Pharmaceuticals beats Codexis on 11 of the 15 factors compared between the two stocks.